Cargando…

Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report

BACKGROUND: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Li-Cai, Piao, Song-Zhe, Zheng, Hai-Hong, Hong, Tao, Feng, Qin, Ke, Mang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173416/
https://www.ncbi.nlm.nih.gov/pubmed/34141803
http://dx.doi.org/10.12998/wjcc.v9.i17.4373
_version_ 1783702720417366016
author Mo, Li-Cai
Piao, Song-Zhe
Zheng, Hai-Hong
Hong, Tao
Feng, Qin
Ke, Mang
author_facet Mo, Li-Cai
Piao, Song-Zhe
Zheng, Hai-Hong
Hong, Tao
Feng, Qin
Ke, Mang
author_sort Mo, Li-Cai
collection PubMed
description BACKGROUND: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis (CG). The cause of PL combined with CG is poorly understood, and there is currently no effective treatment. Refractory CG with upper urinary tract obstruction even requires partial or radical bladder resection. CASE SUMMARY: In this case, a patient suffering from PL with CG was treated by transurethral resection of bladder tumour (TUR-BT) and oral administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The LUTS were alleviated, and the cystoscopy results improved significantly. Immunohistochemistry showed up-regulated COX-2 expression in the epithelium of TUR-BT samples, suggesting that COX-2 may participate in the pathophysiological process of PL combined with CG. CONCLUSION: We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG.
format Online
Article
Text
id pubmed-8173416
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-81734162021-06-16 Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report Mo, Li-Cai Piao, Song-Zhe Zheng, Hai-Hong Hong, Tao Feng, Qin Ke, Mang World J Clin Cases Case Report BACKGROUND: Pelvic lipomatosis (PL) is a rare benign condition with characteristic overgrowth of histologically benign fat and invasion and compression of pelvic organs, often leading to non-specific lower urinary tract symptoms (LUTS). Approximately 40% of patients with PL have cystitis glandularis (CG). The cause of PL combined with CG is poorly understood, and there is currently no effective treatment. Refractory CG with upper urinary tract obstruction even requires partial or radical bladder resection. CASE SUMMARY: In this case, a patient suffering from PL with CG was treated by transurethral resection of bladder tumour (TUR-BT) and oral administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. The LUTS were alleviated, and the cystoscopy results improved significantly. Immunohistochemistry showed up-regulated COX-2 expression in the epithelium of TUR-BT samples, suggesting that COX-2 may participate in the pathophysiological process of PL combined with CG. CONCLUSION: We report for the first time that celecoxib may be an effective treatment strategy for PL combined with refractory CG. Baishideng Publishing Group Inc 2021-06-16 2021-06-16 /pmc/articles/PMC8173416/ /pubmed/34141803 http://dx.doi.org/10.12998/wjcc.v9.i17.4373 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Case Report
Mo, Li-Cai
Piao, Song-Zhe
Zheng, Hai-Hong
Hong, Tao
Feng, Qin
Ke, Mang
Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title_full Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title_fullStr Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title_full_unstemmed Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title_short Pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: A case report
title_sort pelvic lipomatosis with cystitis glandularis managed with cyclooxygenase-2 inhibitor: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173416/
https://www.ncbi.nlm.nih.gov/pubmed/34141803
http://dx.doi.org/10.12998/wjcc.v9.i17.4373
work_keys_str_mv AT molicai pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport
AT piaosongzhe pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport
AT zhenghaihong pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport
AT hongtao pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport
AT fengqin pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport
AT kemang pelviclipomatosiswithcystitisglandularismanagedwithcyclooxygenase2inhibitoracasereport